Who owns BIOMARIN PHARMACEUTICAL?
- CUSIP Number: 09061gak7
Tip: Access positions for across all investors
Analyze quarterly positions in Biomarin Pharmaceutical with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Biomarin Pharmaceutical stock
Who bought or sold BIOMARIN PHARMACEUTICAL this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Tenor Capital Management | 112M | $108M | -4% | Mar 2026 |
|
| Oaktree Capital Management | 56M | $54M | 33% | Mar 2026 |
|
| Capstone Investment Advisors | 54M | $52M | 55% | Mar 2026 |
|
| BlackRock | 51M | $49M | 20% | Mar 2026 |
|
| Man Group | 49M | $47M | 36% | Mar 2026 |
|
| Opti Capital Management | 28M | $27B | -12% | Mar 2026 |
|
| MacKay Shields | 27M | $26M | -24% | Mar 2026 |
|
| Lazard Asset Management | 23M | $221k | -58% | Mar 2026 |
|
| Toronto-Dominion Bank | 20M | $20M | 911% | Mar 2026 |
|
| Verition Fund Management | 20M | $19M | 100% | Dec 2025 |
|
| Victory Capital Management | 18M | $17M | -3% | Dec 2025 |
|
| Thrivent Financial for Lutherans | 16M | $15M | 0% | Mar 2026 |
|
| State Street Corporation | 13M | $12M | 5% | Dec 2025 |
|
| DeepCurrents Investment Group | 10M | $9.7M | 100% | Mar 2026 |
|
| Citigroup | 9.8M | $9.4M | 100% | Mar 2026 |
|
| Bank of America Corporation | 8.6M | $8.3M | 100% | Mar 2026 |
|
| Millennium Management | 7.5M | $7.2M | -57% | Mar 2026 |
|
| Russell Investments | 6.9M | $6.7M | 12% | Mar 2026 |
|
| Royal Bank of Canada | 5.1M | $4.9M | 825% | Mar 2026 |
|
| Wellesley Investment Advisors | 4.0M | $3.9B | 0% | Mar 2026 |
|
| Palisade Capital Management | 3.6M | $3.5M | -2% | Dec 2025 |
|
| Colony | 3.4M | $3.3M | 100% | Dec 2025 |
|
| State of Wisconsin Investment Board | 3.0M | $2.9M | 0% | Dec 2025 |
|
| Bnp Paribas Investment Partners | 2.9M | $2.8M | 0% | Dec 2025 |
|
| Conning | 2.7M | $2.6M | 0% | Mar 2026 |
|
| Wellington Management Company | 2.7M | $2.6M | 2% | Dec 2025 |
|
| Nomura Asset Management International | 1.9M | $1.8M | 100% | Mar 2026 |
|
| Henderson Group | 1.6M | $1.5M | 100% | Mar 2026 |
|
| Wells Fargo & Company | 1.6M | $1.5M | 1% | Mar 2026 |
|
| Morgan Stanley | 1.6M | $1.5M | 100% | Mar 2026 |
|
| Jane Street | 1.0M | $965k | 100% | Mar 2026 |
|
| Kohlberg Kravis Roberts & Co | 534k | $515k | 0% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 373k | $366k | -62% | Mar 2026 |
|
| Sei Investments | 371k | $357k | 0% | Mar 2026 |
|
| Oppenheimer Asset Management | 176k | $170k | -3% | Mar 2026 |
|
| Raymond James Financial | 96k | $92k | 104% | Dec 2025 |
|
| UBS Group | 66k | $64k | -55% | Mar 2026 |
|
| Stephens | 54k | $52k | 0% | Mar 2026 |
|
| Steward Partners Investment Advisory | 52k | $50k | 24% | Mar 2026 |
|
| Ameriprise Financial | 51k | $49k | 31% | Mar 2026 |
|
| Mml Investors Services | 49k | $47k | 0% | Mar 2026 |
|
| Capital Investment Advisory Services | 43k | $41k | 0% | Mar 2026 |
|
| Mariner Wealth Advisors | 42k | $40k | 0% | Mar 2026 |
|
| Balboa Wealth Partners | 32k | $31k | 0% | Mar 2026 |
|
| William Blair $ Company | 19k | $18k | 100% | Mar 2026 |
|
| Wiley Bros.-aintree Capital | 18k | $17k | -49% | Dec 2025 |
|
| LPL Financial | 17k | $16k | 0% | Mar 2026 |
|
| HB Wealth Management | 11k | $11k | 0% | Mar 2026 |
|
| Davenport & Co | 10k | $965k | 0% | Mar 2026 |
|
| Cetera Investment Advisers | 10k | $9.6k | 0% | Mar 2026 |
|
| Us Bancorp | 5.0k | $4.8k | 0% | Dec 2025 |
|
| Oddo Bhf Asset Management Sas | 225.00 | $218k | 0% | Mar 2026 |
|
Who sold out of Biomarin Pharmaceutical?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | Dec 2025 | 14M | $13M |
| Jpmorgan Chase & Co | Sep 2025 | 13M | $13M |
| Ares Systematic Credit | Dec 2025 | 3.4M | $3.3M |
| Macquarie Group | Sep 2025 | 1.9M | $1.8M |
| Universal- Beteiligungs- und Servicegesellschaft mbH | Dec 2025 | 1.2M | $1.2M |
| OZ Management | Dec 2025 | 1.1M | $1.0M |
| Prospector Partners | Sep 2025 | 1.0M | $948k |
| Leucadia National Corporation | Dec 2025 | 939k | $901k |
| Bank of New York Mellon | Dec 2025 | 546k | $524k |
| Barclays | Sep 2025 | 534k | $507k |
| Kornitzer Capital Management | Dec 2025 | 500k | $479k |
| Commonwealth Equity Services | Dec 2025 | 20k | $19k |
| Brian McDonald | Sep 2025 | 9.0k | $8.5k |
| Nomura Holdings | Dec 2025 | 7.5k | $443k |
| CoreCap Advisors | Dec 2025 | 6.0k | $5.7k |